Romiplostim for children with chronic ITP
Part of Blood & lymphatic clinical trials.
This trial tests the safety and effectiveness of a drug called romiplostim for children ages 1 to 18 who have chronic ITP (a condition where the immune system destroys platelets, causing low platelet counts and bleeding risk). It may be an option for children whose ITP has not improved with or who cannot tolerate other treatments like steroids, IVIG, or eltrombopag.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 1 and 18 years old
- You have been diagnosed with chronic ITP (low platelets for more than 12 months)
- Other standard treatments (steroids, IVIG, or eltrombopag) did not work or caused side effects
- Your platelet count is very low (under 30,000) or you have bleeding or high bleeding risk with a count under 50,000
- Your parent or guardian agrees to the study and signs a consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called romiplostim for patients whose platelet counts stay very low (below 30) for a long time after chemotherapy, even after other treatments have failed. The goal is to see if romiplostim can help raise your platelet count to a safer level.
This trial tests romiplostim, a weekly injection, for patients with ITP (a blood disorder where the body destroys its own platelets) who did not respond to or could not tolerate oral medications. It aims to help raise platelet counts and reduce bleeding risk.
This trial tests a medicine called romiplostim (Nplate) as a first treatment for adults newly diagnosed with ITP. It aims to see if it can safely raise platelet counts and reduce bleeding risk.
This trial tests a combination of romiplostim (a platelet-boosting drug) and steroids as the first treatment for adults with newly diagnosed immune thrombocytopenia (ITP). It aims to see if this approach can safely and effectively raise platelet counts.
This trial tests a drug called romiplostim to help raise platelet levels in children and young adults (ages 6–24) whose platelets drop due to chemotherapy. It’s for those with solid tumors or other non-marrow cancers who are still getting strong treatment.
This trial tests a new combination of two medicines—romiplostim N01 (a shot to raise platelets) and rituximab (an infusion that calms the immune system)—for people with primary immune thrombocytopenia (ITP) who have not had enough improvement from oral TPO-RA pills like hetrombopag or eltrombopag. It aims to see if this combination works better and is safe.
Hear when a new Romiplostim N01 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.